JP5779209B2 - 細菌感染症を処置するための組合せ薬 - Google Patents
細菌感染症を処置するための組合せ薬 Download PDFInfo
- Publication number
- JP5779209B2 JP5779209B2 JP2013169657A JP2013169657A JP5779209B2 JP 5779209 B2 JP5779209 B2 JP 5779209B2 JP 2013169657 A JP2013169657 A JP 2013169657A JP 2013169657 A JP2013169657 A JP 2013169657A JP 5779209 B2 JP5779209 B2 JP 5779209B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- formula
- carbapenem
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000035143 Bacterial infection Diseases 0.000 title description 11
- 208000022362 bacterial infectious disease Diseases 0.000 title description 11
- 229940000425 combination drug Drugs 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims description 62
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 44
- -1 oxyimino group Chemical group 0.000 claims description 41
- 239000003242 anti bacterial agent Substances 0.000 claims description 38
- 229940088710 antibiotic agent Drugs 0.000 claims description 38
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 37
- 229960003644 aztreonam Drugs 0.000 claims description 37
- 230000003115 biocidal effect Effects 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 11
- 229960002182 imipenem Drugs 0.000 claims description 11
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims description 11
- 229960002260 meropenem Drugs 0.000 claims description 11
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 11
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 5
- 229960000895 doripenem Drugs 0.000 claims description 5
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 5
- 229960002770 ertapenem Drugs 0.000 claims description 5
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 4
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 208000019206 urinary tract infection Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 125000005646 oximino group Chemical group 0.000 claims description 3
- 241001673062 Achromobacter xylosoxidans Species 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 description 69
- 125000001424 substituent group Chemical group 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 125000000623 heterocyclic group Chemical group 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 238000000634 powder X-ray diffraction Methods 0.000 description 11
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 239000011593 sulfur Substances 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 125000005842 heteroatom Chemical group 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 239000002178 crystalline material Substances 0.000 description 6
- 229910052736 halogen Inorganic materials 0.000 description 6
- 150000002367 halogens Chemical class 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108090000204 Dipeptidase 1 Proteins 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 0 *C(SC1)=N[C@]1C(C(O)=O)=NOCC(N(C=C1O*)O*)=CC1=O Chemical compound *C(SC1)=N[C@]1C(C(O)=O)=NOCC(N(C=C1O*)O*)=CC1=O 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- 102100020743 Dipeptidase 1 Human genes 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108020004256 Beta-lactamase Proteins 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241000588921 Enterobacteriaceae Species 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 229940041011 carbapenems Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229940124307 fluoroquinolone Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229950011346 panipenem Drugs 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- QGXFDKHOSNJQKE-UHFFFAOYSA-N sulfuric acid;2,2,2-trifluoroacetic acid Chemical compound OS(O)(=O)=O.OC(=O)C(F)(F)F QGXFDKHOSNJQKE-UHFFFAOYSA-N 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 150000003952 β-lactams Chemical class 0.000 description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- FITNPEDFWSPOMU-UHFFFAOYSA-N 2,3-dihydrotriazolo[4,5-b]pyridin-5-one Chemical compound OC1=CC=C2NN=NC2=N1 FITNPEDFWSPOMU-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CDFGMYLBUSYTKQ-UHFFFAOYSA-N 2-oxoazetidine-1-sulfonic acid Chemical class OS(=O)(=O)N1CCC1=O CDFGMYLBUSYTKQ-UHFFFAOYSA-N 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CWXYHOHYCJXYFQ-UHFFFAOYSA-N Betamipron Chemical compound OC(=O)CCNC(=O)C1=CC=CC=C1 CWXYHOHYCJXYFQ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 125000006241 alcohol protecting group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 229950007599 betamipron Drugs 0.000 description 2
- 229960003169 biapenem Drugs 0.000 description 2
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SZVRVSZFEDIMFM-ZCFIWIBFSA-N (2s)-3-hydroxy-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)O SZVRVSZFEDIMFM-ZCFIWIBFSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZBCGQDXDMXVJRE-ZPPASOCGSA-N CC(C)([C@@H](C1=O)NC(/C(/C2=CSC(N)N2C)=N\OCC(N(C=C2O)O)=CC2=O)=O)N1OS(O)(=O)=O Chemical compound CC(C)([C@@H](C1=O)NC(/C(/C2=CSC(N)N2C)=N\OCC(N(C=C2O)O)=CC2=O)=O)N1OS(O)(=O)=O ZBCGQDXDMXVJRE-ZPPASOCGSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588919 Citrobacter freundii Species 0.000 description 1
- 102000003850 Dipeptidase 1 Human genes 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 150000008545 L-lysines Chemical class 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- VTAUQWSCSGNTHZ-UHFFFAOYSA-N N1(N=NC2=C1N=CC=C2)OC(=[N+](C)C)N(C)C.CN Chemical compound N1(N=NC2=C1N=CC=C2)OC(=[N+](C)C)N(C)C.CN VTAUQWSCSGNTHZ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710091608 Probable diacyglycerol O-acyltransferase tgs2 Proteins 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000006242 amine protecting group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000244 anti-pseudomonal effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 108010068385 carbapenemase Proteins 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000003115 checkerboard titration Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- OMLKPIIYNUNCMY-UHFFFAOYSA-N formic acid;sulfuric acid Chemical compound OC=O.OS(O)(=O)=O OMLKPIIYNUNCMY-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940041009 monobactams Drugs 0.000 description 1
- AFDQGRURHDVABZ-UHFFFAOYSA-N n,n-dimethylformamide;sulfur trioxide Chemical compound O=S(=O)=O.CN(C)C=O AFDQGRURHDVABZ-UHFFFAOYSA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 238000002411 thermogravimetry Methods 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
RAは、アミン保護基(ホルミル、トリフルオロアセチル、O−ニトロフェノキシアセチル、クロロアセチル、トリクロロアセチル、γ−クロロブチリル、ベンジルオキシカルボニル、p−クロロベンジルオキシカルボニル、p−ニトロベンジルオキシカルボニル、p−ブロモベンジルオキシカルボニル、p−メトキシベンジルオキシカルボニル、ジフェニルメトキシカルボニル、tert−ブチルオキシカルボニル、イソプロピルオキシカルボニル、ジフェニルメチル、トリフェニルメチル、ベンジル、p−メトキシベンジル、3,4−ジメトキシベンジルなど)を表し;そして
RB及びRCは、相互に独立にアルコール保護基(ベンジルオキシカルボニル、p−クロロベンジルオキシカルボニル、p−ニトロベンジルオキシカルボニル、p−ブロモベンジルオキシカルボニル、p−メトキシベンジルオキシカルボニル、ジフェニルメトキシカルボニル、tert−ブチルオキシカルボニル、イソプロピルオキシカルボニル、ジフェニルメチル、トリフェニルメチル、ベンジル、p−メトキシベンジル、3,4−ジメトキシベンジル、トリアルキルシラン(トリメチルシラン、トリエチルシラン又はtert−ブチルジメチルシランなど)など)を表す。
vstは、100%〜90%の相対強度を表し;
stは、90%未満〜65%の相対強度を表し;
mは、65%未満〜50%の相対強度を表し;そして
wは、50%未満〜30%の相対強度を表す]のとおりのX線粉末回折パターンを示し、更に具体的にはCu Kα線で記録された、以下のX線粉末回折パターンを示すが、これは、20%以上の相対強度の回折ピークを示している:
R1は、水素又はC1−C6アルキルを表し;
R2は、水素又はC1−C6アルキルを表し;
R3は、水素、C1−C6アルキル、C1−C6アルコキシ;−(C1nH2n)−R5又は−O−(C1nH2n)−R5を表し;そしてここで
R5は、ハロゲン、シアノ、C1−C6アルコキシ、アミノ、(C1−C6アルキル)アミノ、ジ(C1−C6アルキル)アミノ、又は式:−CO−R6、−NH−CO−R6、−CO−NH2、−NH−CO−NH2、−NH−SO2−NH2若しくは−NH−(C=NH)−NH2の基を表すが、これらの基において1個以上の水素原子はまた、R6で置換されていてもよいか、又はこの基の−NH2残基は、環内に存在する窒素原子を介して基に結合した5〜6員複素環で置換されていてもよく、そしてこの複素環は、非置換であっても、又は1個以上の置換基S2(ここで、各S2は、他の置換基S2と独立に、後述の意味の1つを有する)で置換されていてもよく;そして
R6は、C1−C6アルキル、フェニル又は5〜6員複素環を表し、かつ非置換であっても、又は1個以上の置換基S1(ここで、各S1は、他の置換基S1と独立に、後述の意味の1つを有する)で置換されていてもよく;そして
nは、1〜6の整数であり;
R4は、式:−(S)m−R7の基を表し;そしてここで
mは、0又は1であり、そして
R7は、水素;C1−C6アルキル(非置換であるか、又は1個以上の置換基S1で置換されている);フェニル(非置換であるか、又は1個以上の置換基S1で置換されている);又は窒素、硫黄及び酸素から選択される1個以上のヘテロ原子を含有する3〜6員ヘテロシクリル基(このヘテロシクリル基は更に、場合によりフェニル環又は5〜6員複素環に縮合していてもよく、そして基全体は、非置換であるか、又は1個以上の置換基S1で置換されている)を表し;そしてここで、
各S1は、他の置換基S1と独立に、C1−C6アルキル(非置換であるか、又は1個以上の置換基S2で置換されている);フェニル(非置換であるか、又は1個以上の置換基S2で置換されている);又は窒素、硫黄及び酸素から選択される1個以上のヘテロ原子を含有する3〜6員ヘテロシクリル基(このヘテロシクリル基は更に、場合によりフェニル環又は5〜6員複素環に縮合していてもよく、そして基全体は、非置換であるか、又は1個以上の置換基S2で置換されている);C1−C6アルコキシ、ヒドロキシル、カルボキシ、アミノ、C1−C6アルキルアミノ、ジ(C1−C6アルキル)アミノ、シアノ、ハロゲン、又は式:−CO−R8、−NH−CO−NH2、−CO−NH2、−NH−CH=NH、−(C=NH)−C1−C6アルキル、−NH−CO−NH2、−NH−SO2−NH2若しくは−NH−(C=NH)−NH2の基から選択されるが、これらの基において1個以上の水素原子はまた、R8で置換されていてもよいか、又はこの基の−NH2残基は、環内に存在する窒素原子を介して基に結合した5〜6員複素環で置換されていてもよく、そしてこの複素環は、非置換であっても、又は1個以上の置換基S2(ここで、各S2は、他の置換基S2と独立に、後述の意味の1つを有する)で置換されていてもよく;そして
R8は、C1−C6アルキル(非置換であるか、又は1個以上の置換基S2で置換されている);フェニル(非置換であるか、又は1個以上の置換基S2で置換されている);又は窒素、硫黄及び酸素から選択される1個以上のヘテロ原子を含有する3〜6員ヘテロシクリル基(このヘテロシクリル基は更に、場合によりフェニル環又は5〜6員複素環に縮合していてもよく、そして基全体は、非置換であるか、又は1個以上の置換基S2で置換されている)を表し;そしてここで
各S2は、他の置換基S2と独立に、C1−C6アルキル(非置換であるか、又は1個以上の置換基S3で置換されている);フェニル(非置換であるか、又は1個以上の置換基S3で置換されている);又は窒素、硫黄及び酸素から選択される1個以上のヘテロ原子を含有する3〜6員ヘテロシクリル基(このヘテロシクリル基は更に、場合によりフェニル環又は5〜6員複素環に縮合していてもよく、そして基全体は、非置換であるか、又は1個以上の置換基S3で置換されている);C1−C6アルコキシ、ヒドロキシル、カルボキシ、アミノ、C1−C6アルキルアミノ、ジ(C1−C6アルキル)アミノ、シアノ、ハロゲン、又は式:−CO−R9、−NH−CO−R9、−CO−NH2、−NH−CH=NH、−NH−CO−NH2、−NH−SO2−NH2若しくは−NH−(C=NH)−NH2の基から選択されるが、これらの基において1個以上の水素原子はまた、R9で置換されていてもよいか、又はこの基の−NH2残基は、環内に存在する窒素原子を介して基に結合した5〜6員複素環で置換されていてもよく、そしてこの複素環は、非置換であっても、又は1個以上の置換基S3(ここで、各S3は、他の置換基S3と独立に、後述の意味の1つを有する)で置換されていてもよく;そして
R9は、C1−C6アルキル(非置換であるか、又は1個以上の置換基S3で置換されている);フェニル(非置換であるか、又は1個以上の置換基S3で置換されている);又は窒素、硫黄及び酸素から選択される1個以上のヘテロ原子を含有する3〜6員ヘテロシクリル基(このヘテロシクリル基は更に、場合によりフェニル環又は5〜6員複素環に縮合していてもよく、そして基全体は、非置換であるか、又は1個以上の置換基S3で置換されている)を表し;そしてここで
各S3は、他の置換基S3と独立に、非置換C1−C6アルキル、非置換フェニル又は非置換5〜6員複素環;C1−C6アルコキシ、ヒドロキシル、カルボキシ、アミノ、C1−C6アルキルアミノ、ジ(C1−C6アルキル)アミノ、シアノ、ハロゲン、又は式:−NH−CO−NH2、−CO−NH2、−NH−CH=NH、−NH−CO−NH2、−NH−SO2−NH2若しくは−NH−(C=NH)−NH2の基を表すか;あるいは
R3及びR4は、一緒にC3−C7ポリメチレン基を形成するが、これは、非置換であるか、又は1個以上の置換基S3(ここで、各S3は、他の置換基S3と独立に、上述の意味の1つを有する)で置換されている]で示される化合物、又は薬学的に許容しうるその塩である。
R1が、水素又はC1−C6アルキルを表し;
R2が、水素又はC1−C6アルキルを表し;そして
R3が、C1−C6アルキルを表す、式(II)の化合物であり、特に、R1及びR2の一方が、水素を表し、かつもう一方が、−CH3を表し、そしてR3が、−CH3である時である。
Yは、窒素又は>CH−を表し;
S4は、水素を表すか、又は上記と同義のS1の意味を有しており;そして
Rは、水素;C1−C4アルキル(特にメチル)、又は−(N=H)−C1−C4アルキル(特に−(N=H)−CH3)を表すか、あるいは
S4及びRは、これらが結合している窒素原子又はY基と一緒に、5〜6員複素環を形成する(Rは、最も好ましくは水素又はメチルである)]で示される化合物、又は薬学的に許容しうるその塩は、本発明の目的に特に好ましい、別の群のカルバペネムの実施態様を形成する。
ヒドロキシスルホン酸(3S)−3−{(2Z)−2−(2−アミノ(1,3−チアゾール−4−イル))−3−[(1,5−ジヒドロキシ−4−オキソ(2−ヒドロピリジル))メトキシ]−3−アザプロパ−2−エノイルアミノ}−4,4−ジメチル−2−オキソアゼチジニル(式(I)の化合物)の調製
モノバクタム系抗生物質(I)は、スキーム4に略述される合成法により、及び後述される手順により調製した。
カップリング試薬としてHOBtを使用
(2Z)−3−{[1,5−ビス(ジフェニルメトキシ)−4−オキソ(2−ヒドロピリジル)]メトキシ}−2−{2−[(トリフェニルメチル)アミノ](1,3−チアゾール−4−イル)}−3−アザプロパ−2−エン酸(1)(0.89g、0.95mmol、J. Antibiotics 1990, 1450及びWO-A-02/22613)、ヒドロキシベンゾトリアゾール(HOBT)(0.14g、1.03mmol)及びジシクロヘキシルカルボジイミド(0.26g、1.41mmol)をDMF(25mL)に室温で溶解した。最初にヒドロキシスルホン酸(3S)−3−アミノ−4,4−ジメチル−2−オキソアゼチジニル(2)(0.20g、0.95mmol、J. Org. Chem. 2003, 177及びTetrahedron Lett. 1986, 2786)を、次いで30分後にNaHCO3(0.09g、1.05mmol)を前記溶液に加えた。生じた混合物を18時間撹拌した。生成した沈殿物を濾過して、酢酸エチルを濾液に加えた。有機相を飽和NaCl水溶液で2回洗浄し、Na2SO4で乾燥して、溶媒を真空で留去した。残渣を酢酸エチル(30mL)で粉砕することにより、所望の化合物(3)0.5gを白色の固体として濾過後に得た。
HPLC純度:98%。
HATU(1.38g、3.64mmol)を含有するDMSO(10mL)の溶液を、室温でDMSO(20mL)中の(2Z)−3−{[1,5−ビス(ジフェニルメトキシ)−4−オキソ(2−ヒドロピリジル)]メトキシ}−2−{2−[(トリフェニルメチル)アミノ](1,3−チアゾール−4−イル)}−3−アザプロパ−2−エン酸(1)(3.0g、3.16mmol、J. Antibiotics 1990, 1450及びWO-A-02/22613)及びヒドロキシスルホン酸(3S)−3−アミノ−4,4−ジメチル−2−オキソアゼチジニル(2)(1.18g、5.06mmol、J. Org. Chem. 2003, 177及びTetrahedron Lett. 1986, 2786)の懸濁液に加えた。次にNaHCO3(0.81g、9.65mmol)を固体として加えた。生じた混合物は1時間後に溶液になったが、これを室温で24時間撹拌した。次いで酢酸エチル(50mL)を加え、生じた溶液を食塩水(6×30mL)で6回洗浄した。有機相をNa2SO4で乾燥して、混合物を真空での溶媒の留去により濃縮して、溶液約25mLがフラスコに残るようにした。室温で、シクロヘキサン(40mL)を、この黄色の溶液に滴下により加えた。生じた沈殿物を濾過により集めて、次にこのケーキをシクロヘキサン(2×5mL)で洗浄することにより、所望の化合物(3)3.3gを得た。
HPLC純度:95%。
両方の方法により、同一のNMR及びMSスペクトルを持つ生成物を得た。
(a)トリフルオロ酢酸の使用
ヒドロキシスルホン酸(3S)−3−{(2Z)−3−{[1,5−ビス(ジフェニルメトキシ)−4−オキソ(2−ヒドロピリジル)]メトキシ}−2−{2−[(トリフェニルメチル)アミノ](1,3−チアゾール−4−イル)}−3−アザプロパ−2−エノイルアミノ}−4,4−ジメチル−2−オキソアゼチジニル(3)(0.25g、0.23mmol)及びトリエチルシラン(0.08g、0.69mmol)をジクロロメタン(15mL)に溶解して、−10°で冷却した。次にこの冷却混合物にトリフルオロ酢酸(1.04g、9.2mmol)をゆっくり加えた。温度をゆっくり25℃まで上げて、反応液を更に4時間撹拌した。溶媒を真空で除去して、残渣を、ヘキサン及び酢酸エチル(1:4)を含有する溶媒混合物で粉砕することにより、所望の化合物(I)0.11gを固体として得た。
HPLC純度:94%。
5℃のギ酸(3mL)中に、ヒドロキシスルホン酸(3S)−3−{(2Z)−3−{[1,5−ビス(ジフェニルメトキシ)−4−オキソ(2−ヒドロピリジル)]メトキシ}−2−{2−[(トリフェニルメチル)アミノ](1,3−チアゾール−4−イル)}−3−アザプロパ−2−エノイルアミノ}−4,4−ジメチル−2−オキソアゼチジニル(3)(0.40g、0.31mmol)を加え、この清澄な溶液を5〜10℃で5時間撹拌した。次に酢酸エチル(40mL)を加えて、生じた沈殿物を濾別した。この白色の沈殿物を更なる酢酸エチル(2×5mL)で洗浄して、真空乾燥後に所望の化合物(I)0.09gを得た。
HPLC純度:92%。
両方の方法により、同一のNMR及びMSスペクトルを持つ生成物を得た。
前もって調製した式(I)の化合物の粗生成物(1.31g)を室温でアセトニトリル(15mL)に懸濁した。次に水(3.30mL)を前記懸濁液に加えた。結晶化が開始するまで、この清澄な溶液(溶液が清澄でないなら、懸濁液を穏やかに温めればよい)を室温で数分間撹拌した。この懸濁液を室温で1時間及び0℃で更に1時間撹拌した。濾過後、式(I)の化合物1.05gを白色の結晶性物質として得たが、これは、無定形物質について以前に報告されたものと同一のNMR及びMSスペクトルを有する。
式(I)の化合物の結晶性物質のFTIRスペクトル:
(a)式(I)の化合物のナトリウム塩の調製
炭酸水素ナトリウム(0.0077g、0.095mmol)を何回かに分けて、式(I)の化合物(0.05g、0.1mmol)を含有する5℃で冷却した水溶液(pH2〜3)(20mL)に加えた。この清澄な溶液を5℃で15分間撹拌した(pH5〜6)。溶液を一晩凍結乾燥することにより、白色の固体0.052gを得た。
式(I)の化合物(0.20g、0.39mmol)及びL−アルギニン(0.0672g、0.39mmol)を室温で固体として一緒に激しく混合した。生じた粉末を水(40mL)に溶解して、室温で2〜3分間撹拌した。この溶液を一晩凍結乾燥することにより、白色の固体0.260gを得た。
式(I)の化合物(0.20g、0.39mmol)及びL−リシン(0.0564g、0.39mmol)を室温で固体として一緒に激しく混合した。生じた粉末を水(45mL)に溶解して、室温で2〜3分間撹拌した。この溶液を一晩凍結乾燥することにより、白色の固体0.250gを得た。
化合物の及びこれらの組合せの抗菌活性を、National Committee for Clinical Laboratory Standards(NCCLSドキュメントM7-A6)に記載された標準手順により様々な生物に対して求めた。化合物は、その水溶解度により100% DMSO又は無菌ブロスに溶解して、微生物増殖培地(IsoSensiTest Broth + 16μg/mL 2,2’−ビピリジル)に最終反応濃度(0.06〜32μg/mL)まで希釈した。全ての場合に、細菌と共にインキュベートしたDMSOの最終濃度は、1%以下とした。最小阻止濃度(MIC)の推定のために、化合物の2倍希釈液を、106細菌/mLを含有するマイクロプレートのウェルに加えた。プレートを適切な温度(30℃又は37℃)で一晩インキュベートし、光学密度を目測した。MIC値は、試験生物の目に見える増殖を完全に阻止する最低化合物濃度として定義される。相乗作用試験は、チェッカーボード形式に分配した2種の抗菌剤を用いた他は、上述のものと同じ条件下で実行した[Isenberg HD (1992) Synergism testing: Broth microdilution checkerboard and broth macrodilution methods. In: Clinical Microbiology Procedures Manual vol. 1. Washington, DC: American Society for Microbiology. Sections 5.18.1 to 5.18.28.]。使用した菌株は以下である:Pseudomonas aeruginosa 6067(DSMZのアクセッション番号;DSMZ- Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Inhoffenstr. 7 B, D-38124 Braunschweig:DSM18987)、Pseudomonas aeruginosa (67/2B)2R.A.(DSM18988)、Achromobacter(旧名Alcaligenes)xylosoxidans QK3/96(DSM18991)、Enterobacter aerogenes Zayakosky 5(DSM18992)。
により求めた[Isenberg HD (1992); Eliopoulos, G.M. & Moellering, R.C. (1996). In Antibiotics in Laboratory Medicine, 4th edn, (Lorian, V., Ed.), pp. 330-96. Williams and Wilkins, Baltimore, MD.]。
S=FIC≦0.5: 相乗作用
s=0.5<FIC<1: 部分相乗作用
D=FIC=1: 相加作用
I=1<FIC<4: 不偏
N=4≦FIC: 拮抗作用
Claims (9)
- 1種のカルバペネム系抗生物質、又は薬学的に許容しうるその塩を用いる、請求項1記載の使用。
- カルバペネム系抗生物質が、メロペネム、又は薬学的に許容しうるその塩である、請求項1又は2記載の使用。
- 1種のカルバペネム系抗生物質、又は薬学的に許容しうるその塩を用いる、請求項4記載の使用。
- カルバペネム系抗生物質が、メロペネム、又は薬学的に許容しうるその塩である、請求項4又は5記載の使用。
- カルバペネム耐性グラム陰性細菌が、シュードモナス・エルギノーサ(Pseudomonas aeruginosa)、アクロモバクター・キシロソキシダンス(Achromobacter xylosoxidans)、及びエンテロバクター・アエロゲネス(Enterobacter aerogenes)からなる群から選択される、請求項4〜6のいずれか1項記載の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07006053.8 | 2007-03-23 | ||
EP07006053 | 2007-03-23 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554024A Division JP2010521517A (ja) | 2007-03-23 | 2008-03-19 | 細菌感染症を処置するための組合せ薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013253094A JP2013253094A (ja) | 2013-12-19 |
JP2013253094A5 JP2013253094A5 (ja) | 2014-02-06 |
JP5779209B2 true JP5779209B2 (ja) | 2015-09-16 |
Family
ID=38293982
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554024A Pending JP2010521517A (ja) | 2007-03-23 | 2008-03-19 | 細菌感染症を処置するための組合せ薬 |
JP2013169657A Expired - Fee Related JP5779209B2 (ja) | 2007-03-23 | 2013-08-19 | 細菌感染症を処置するための組合せ薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009554024A Pending JP2010521517A (ja) | 2007-03-23 | 2008-03-19 | 細菌感染症を処置するための組合せ薬 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8486929B2 (ja) |
EP (1) | EP2124942B1 (ja) |
JP (2) | JP2010521517A (ja) |
KR (1) | KR101320718B1 (ja) |
CN (1) | CN101641095B (ja) |
AU (1) | AU2008231854B2 (ja) |
BR (1) | BRPI0809147A2 (ja) |
CA (1) | CA2680018C (ja) |
HK (1) | HK1138184A1 (ja) |
MX (1) | MX2009009918A (ja) |
NZ (1) | NZ579375A (ja) |
RU (1) | RU2488394C2 (ja) |
WO (1) | WO2008116813A2 (ja) |
ZA (1) | ZA200906349B (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101320718B1 (ko) * | 2007-03-23 | 2013-10-21 | 바실리어 파마슈티카 아게 | 세균 감염 치료용 조합 약제 |
TR201102640T1 (tr) * | 2008-12-01 | 2011-08-22 | Glade Organics Private Limited | Aztreonamın meropenem ve ertapenem adlı karbapenemlerle oluşturduğu sinerjik kombinasyonlar. |
SG171781A1 (en) | 2008-12-19 | 2011-07-28 | Pfizer | Monocarbams |
RS60310B1 (sr) | 2010-08-10 | 2020-07-31 | Rempex Pharmaceuticals Inc | Ciklični derivati estra boronske kiseline, postupak za pripremu injihove terapeutske upotrebe |
KR101315483B1 (ko) * | 2011-06-23 | 2013-10-07 | 주식회사 아리바이오 | 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물 |
US9012491B2 (en) | 2011-08-31 | 2015-04-21 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9642869B2 (en) | 2013-01-04 | 2017-05-09 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP2941247A4 (en) | 2013-01-04 | 2017-02-08 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
EP3139930A4 (en) | 2014-05-05 | 2018-01-17 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
HUE046836T2 (hu) | 2014-05-05 | 2020-03-30 | Rempex Pharmaceuticals Inc | Boronát sók szintézise és alkalmazásuk |
CN106459096B (zh) | 2014-05-19 | 2019-03-08 | 莱姆派克斯制药公司 | 硼酸衍生物及其治疗用途 |
EA201692301A1 (ru) | 2014-07-01 | 2017-06-30 | Ремпекс Фармасьютикалз, Инк. | Производные бороновой кислоты и их терапевтическое применение |
WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
RU2618433C2 (ru) * | 2015-08-10 | 2017-05-03 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) | Антимикробная комбинация в отношении устойчивых к карбапенемам грамотрицательных бактерий вида pseudomonas aeruginosa, продуцирующих металло-β-лактамазу |
EP3478693B1 (en) | 2016-06-30 | 2021-07-21 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
CN107641119B (zh) | 2016-07-21 | 2019-11-08 | 中国科学院上海药物研究所 | 单环β-内酰胺-铁载体轭合物及其制备方法和用途 |
RU2666619C2 (ru) * | 2016-12-01 | 2018-09-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный университет" (СПбГУ) | АНТИМИКРОБНАЯ КОМБИНАЦИЯ В ОТНОШЕНИИ УСТОЙЧИВЫХ К КАРБАПЕНЕМАМ ГРАМОТРИЦАТЕЛЬНЫХ БАКТЕРИЙ ВИДА ACINETOBACTER BAUMANNII, ПРОДУЦИРУЮЩИХ МЕТАЛЛО-β-ЛАКТАМАЗУ |
WO2018065636A1 (en) | 2016-12-21 | 2018-04-12 | Aicuris Anti-Infective Cures Gmbh | COMBINATION THERAPY WITH AMIDINE SUBSTITUTED ß-LACTAM COMPOUNDS AND ß-LACTAMASE INHIBITORS FOR INFECTIONS WITH ANTIBIOTIC RESISTANT BACTERIAL STRAINS |
IL273551B2 (en) | 2017-10-11 | 2024-02-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis |
JP7280273B2 (ja) | 2018-01-29 | 2023-05-23 | メッドシャイン ディスカバリー インコーポレイテッド | 細菌感染を治療するための単環β-ラクタム化合物 |
JP7179185B2 (ja) | 2018-12-18 | 2022-11-28 | メッドシャイン ディスカバリー インコーポレイテッド | 医薬の製造おける単環式β-ラクタム化合物の使用 |
WO2020168265A1 (en) | 2019-02-14 | 2020-08-20 | Singapore Eye Research Institute | Antibacterial compositions |
US20230022708A1 (en) | 2019-12-19 | 2023-01-26 | Medshine Discovery Inc. | Application of compound in drug preparation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1575803A (en) | 1976-03-09 | 1980-10-01 | Fujisawa Pharmaceutical Co | 3,7 disubstituted 3 cephem 4 carboxylic acid compounds andprocesses for the preparation thereof |
US4822786A (en) | 1986-07-01 | 1989-04-18 | Kaken Pharmaceutical Co., Ltd. | Cephalosporin compounds, and antibacterial agents |
US5888998A (en) * | 1997-04-24 | 1999-03-30 | Synphar Laboratories, Inc. | 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors |
US5994340A (en) * | 1997-08-29 | 1999-11-30 | Synphar Laboratories, Inc. | Azetidinone derivatives as β-lactamase inhibitors |
ATE298750T1 (de) * | 2000-09-14 | 2005-07-15 | Pantherix Ltd | 3-(heteroarylacetamido)-2-oxo-azetidin-1- sulfonsäure derivate als antibakterielle mittel |
US20050065141A1 (en) * | 2003-07-31 | 2005-03-24 | Odink Debra A. | Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof |
US8901293B2 (en) * | 2005-12-07 | 2014-12-02 | Basilea Pharmaceutica Ag | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors |
KR101320718B1 (ko) * | 2007-03-23 | 2013-10-21 | 바실리어 파마슈티카 아게 | 세균 감염 치료용 조합 약제 |
-
2008
- 2008-03-19 KR KR1020097019585A patent/KR101320718B1/ko not_active IP Right Cessation
- 2008-03-19 BR BRPI0809147-1A patent/BRPI0809147A2/pt not_active IP Right Cessation
- 2008-03-19 EP EP08718057.6A patent/EP2124942B1/en active Active
- 2008-03-19 AU AU2008231854A patent/AU2008231854B2/en not_active Ceased
- 2008-03-19 US US12/532,243 patent/US8486929B2/en not_active Expired - Fee Related
- 2008-03-19 RU RU2009139004/15A patent/RU2488394C2/ru not_active IP Right Cessation
- 2008-03-19 JP JP2009554024A patent/JP2010521517A/ja active Pending
- 2008-03-19 CN CN2008800093460A patent/CN101641095B/zh not_active Expired - Fee Related
- 2008-03-19 NZ NZ579375A patent/NZ579375A/en not_active IP Right Cessation
- 2008-03-19 WO PCT/EP2008/053336 patent/WO2008116813A2/en active Application Filing
- 2008-03-19 CA CA2680018A patent/CA2680018C/en not_active Expired - Fee Related
- 2008-03-19 MX MX2009009918A patent/MX2009009918A/es active IP Right Grant
-
2009
- 2009-09-11 ZA ZA200906349A patent/ZA200906349B/xx unknown
-
2010
- 2010-04-07 HK HK10103422.0A patent/HK1138184A1/xx not_active IP Right Cessation
-
2013
- 2013-06-12 US US13/915,833 patent/US8809315B2/en not_active Expired - Fee Related
- 2013-08-19 JP JP2013169657A patent/JP5779209B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2680018A1 (en) | 2008-10-02 |
RU2488394C2 (ru) | 2013-07-27 |
WO2008116813A2 (en) | 2008-10-02 |
US20130274238A1 (en) | 2013-10-17 |
KR20090122357A (ko) | 2009-11-27 |
EP2124942B1 (en) | 2016-04-27 |
BRPI0809147A2 (pt) | 2014-08-26 |
CA2680018C (en) | 2014-01-07 |
AU2008231854A1 (en) | 2008-10-02 |
US8809315B2 (en) | 2014-08-19 |
HK1138184A1 (en) | 2010-08-20 |
US8486929B2 (en) | 2013-07-16 |
CN101641095A (zh) | 2010-02-03 |
RU2009139004A (ru) | 2011-04-27 |
JP2010521517A (ja) | 2010-06-24 |
JP2013253094A (ja) | 2013-12-19 |
WO2008116813A3 (en) | 2009-01-22 |
NZ579375A (en) | 2012-02-24 |
KR101320718B1 (ko) | 2013-10-21 |
EP2124942A2 (en) | 2009-12-02 |
WO2008116813A9 (en) | 2008-11-27 |
US20100144699A1 (en) | 2010-06-10 |
ZA200906349B (en) | 2010-06-30 |
CN101641095B (zh) | 2012-10-31 |
MX2009009918A (es) | 2009-10-19 |
AU2008231854B2 (en) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5779209B2 (ja) | 細菌感染症を処置するための組合せ薬 | |
CN103724330B (zh) | 单环-内酰胺类抗生素与β-内酰胺酶抑制剂的有效的联合应用 | |
JP2004509122A (ja) | 抗菌剤としての、3−(ヘテロアリールアセトアミド)−2−オキソ−アゼチジン−1−スルホン酸誘導体 | |
JP2010254697A (ja) | 架橋されたグリコペプチド−セファロスポリン抗生物質 | |
US20130244929A1 (en) | Bridged lipoglycopeptides that potentiate the activity of beta-lactam antibacterials | |
TW474935B (en) | Cephalosporin antibiotics | |
RU2281948C2 (ru) | Цефалоспориновые антибиотики, фармацевтическая композиция на их основе и способ лечения инфекции | |
JPH0899978A (ja) | セファロスポリン誘導体 | |
JPH08245633A (ja) | セファロスポリン誘導体 | |
EP2252287A1 (en) | Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics | |
RU2172317C2 (ru) | Производные цефалоспорина, содержащая их антибактериальная композиция, производные 2-аминотиазолов в качестве промежуточных соединений и способ их получения | |
IE914307A1 (en) | Heterocyclic carboxylic esters, methods for their¹preparation and their use for the preparation of¹gastro-intestinal medicines | |
JP2005509039A (ja) | C−3がs/oおよびs/nである新規なセファロスポリンのホルムアルデヒドアセタール誘導体およびその抗生物質としての使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130912 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140902 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141201 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141224 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150303 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150630 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5779209 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |